期刊文献+

HPLC法测定阿法替尼片的含量 被引量:2

Determination of Afatinib Tablets by HPLC
下载PDF
导出
摘要 目的:建立高效液相色谱法测定阿法替尼片含量的方法。方法采用Phenomenex Luna C18色谱柱(4.6 mm ×250 mm,5μm),流动相为0.02 mol·L-1磷酸二氢钾(2 mol·L-1氢氧化钠溶液调pH 6.0)-乙腈(50:50),柱温为30℃,检测波长为252 nm,流速为1.0 mL·min-1。结果阿法替尼浓度在20~120μg·mL-1范围内线性关系(r=0.9999)良好,平均回收率为100.3%,RSD为0.93%。结论本方法专属强,准确度高,简便,快速。 Objective To establish an HPLC method for the determination of Afatinib Tablets. Methods A stable HPLC method was established,and the chromatography was accomplished on Phenomenex Luna C18 column(4. 6 mm × 250 mm,5 μm),the mobile phase consisted of 0. 02 mol·L-1 of potassium dihydrogen phosphate( adjusted to pH 6. 0 with 2 mol·L-1 sodium hydroxide solution)-acetonitrile( 50:50 ),the column temperature was 30 ℃,the detection wavelength was 252 nm and the flow rate was 1. 0 mL·min-1. Results The linear range of afatinib was 20~120 μg·mL-1(r=0. 999 9),the average recovery was 100. 3% with corresponding RSD of 0. 93%. Conclusion The method was specific,ac-curate,convenient and rapid.
出处 《药学研究》 CAS 2014年第6期337-338,共2页 Journal of Pharmaceutical Research
关键词 高效液相色谱法 阿法替尼片 含量 HPLC Afatinib Tablets Content
  • 相关文献

参考文献4

二级参考文献1

共引文献4

同被引文献20

  • 1许学农.阿法替尼的制备方法:中国,103242303A[P].2013-08-14.
  • 2US FDA. FDA approves new stage lung cancer[ EB/OL ]. treatment for a type of late- ( 2014-05-12 ) http ://www. fda. gov/NewsEvents/Newsroom/PressAnnouncements/ ucm360499, htm.
  • 3YANG J C,HIRSH V,SCHULER M,et al. Symptom con- trol and quality of life in LUX-Lung 3 : a phase llI study of afatinib or cisplatin/pemetrexed in patients with ad- vanced lung adeno-careinoma with EGFR mutations [ J ]. J. Clin. Oncol. ,2013,31(27) :3 342-3 350.
  • 4MILLER V A, HIRSH V, CADRANEL J, et al. Afatinib versus placebo for patients with advance, metastatic non- small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy ( LUX- Lungl ) :a phase 2b/3 randomised trial [ J ]. Lancet. On- col. ,2012,13(5) :528-538.
  • 5ZHANG Qiang,ZHU Hong-wen. Novel quinazoline deriv- atives : WO, 201 184 796A2 [ P]. 2011-07-14.
  • 6ZHANG Xu, PENG Ting, JI Xun,et al. Synthesis and bio- logical evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor [ J ]. Bioorg. Med. Chem, , 2013,21 (24) :7 988-7 998.
  • 7PANDEY A, VOLKOTS D L, SEROOGY J M, et al. Iden-tification of orally active,potent, and selective 4-piperazi- nylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family[ J ]. J. Med. Chem. , 2002,45 ( 17 ) : 3 772-3 793.
  • 8许学农.-种替尼类抗肿瘤药合成所需中间体4-氯-6-氨基-7-羟基喹唑啉的制备方法:中国,103288755A[P].2013-09-11.
  • 9许学农.-种阿法替尼的制备方法:中国,103288808A[P].2013-09-11.
  • 10SCHROEDER J, DZIEWAS G, FACHINGER T, et al. Process for preparing aminocrotonylamino-substituted quinazoline derivatives: WO, 2 007 085 638A1 [ P].2007 -08-02.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部